You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 11, November 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Serial Determinations of Melanoma Tumor—Associated Antigen and Antibody in Patients With Stage I Melanoma

Jan H. Wong, MD; Rishab K. Gupta, PhD; Donald L. Morton, MD

Arch Surg. 1986;121(11):1342-1345.


Abstract

• The correlation of circulating immune complexes (CICs) and the clinical course of malignant melanoma has not been consistent when using nonspecific assays for CIC. To improve predictability, serial serum samples from patients with pathologic stage I melanoma were analyzed for the presence of antimelanoma tumor—associated antigen (TAA) antibody by direct radioimmunoassay and for the presence of melanoma TAA in CIC by the antigen competition method. Immunochemically characterized TAA was isolated from the spent culture medium of a melanoma cell line. Seventy-five percent of patients with melanoma TAA-specific immune complex (IC) had recurrences, while 71% of patients without melanoma TAA-specific IC remained free of disease for prolonged periods (up to 14 years of follow-up). Anti-TAA antibody titers did not correlate with disease recurrence. Our results demonstrate a correlation with melanoma TAA-specific IC and disease recurrence. The absence of melanoma TAA-specific IC is associated with a low risk of recurrence. Fluctuations in melanoma TAA-specific IC levels indicate a dynamic tumor host immunobiology and the need for serial follow-up.

(Arch Surg 1986;121:1342-1345)



Author Affiliations

From the Division of Surgical Oncology, John Wayne Cancer Clinic, and the Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles.


Footnotes

Accepted for publication Aug 12, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 14, 1986.

Reprint requests to Division of Surgical Oncology, CHS 54-140, UCLA School of Medicine, Los Angeles, CA 90024 (Dr Wong).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prospective Evaluation of the Use of Antigen-Specific Immune Complexes in Predicting the Development of Recurrent Melanoma
Wong et al.
Arch Surg 1991;126:1450-1454.
ABSTRACT  

Tumor-Associated Antigen Immune Complexes: A Potential Marker of Recurrent Melanoma
Wong et al.
Arch Surg 1990;125:187-191.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.